Helomics Revenue and Competitors

Location

$211.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Helomics's estimated annual revenue is currently $13.6M per year.(i)
  • Helomics's estimated revenue per employee is $155,000
  • Helomics's total funding is $211.5M.

Employee Data

  • Helomics has 88 Employees.(i)
  • Helomics grew their employee count by 0% last year.

Helomics's People

NameTitleEmail/Phone
1
COOReveal Email/Phone
2
VP Operations & Pathology Services & Medical DirReveal Email/Phone
3
Senior Director BioinformaticsReveal Email/Phone
4
Chief Innovation OfficerReveal Email/Phone
5
Clinical Projects ManagerReveal Email/Phone
6
IT Infrastructure ManagerReveal Email/Phone
7
Sr Medical Laboratory ScientistReveal Email/Phone
8
Senior Software DeveloperReveal Email/Phone
9
Senior AccountantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Helomics?

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. We are dedicated to improving patient outcomes by utilizing a proprietary set of laboratory platforms and our product science as a service commercialization model to allow physicians to characterize malignant tumors. Our novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

keywords:N/A

$211.5M

Total Funding

88

Number of Employees

$13.6M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Helomics News

2022-04-17 - Cancer/Tumor Profiling Market Size And Forecast | Qiagen NV ...

... Molecular Diagnostics, Inc., Genomic Health, Helomics Corporation, Caris Life Sciences, Nanostring Technologies, Oxford Gene Technology.

2022-03-30 - Predictive Oncology Reports Year End 2021 Financial Results and ...

“This value was augmented by the Helomics Discovery 21 Patient-centric Drug Discovery Active Learning (PeDAL) proof-of-concept, and a strategic...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.8M886%N/A
#2
$28.4M882%N/A
#3
$18.5M887%N/A
#4
$12.8M8814%N/A
#5
$22.4M889%N/A